Experimental & Clinical Cancer Editorial Board
- Maher SalamoonDamascus University
Maher Salamoon obtained the master degree in medical oncology from Damascus university, school of medicine in 2003 and a master in hematology/oncology from Curie institution in Paris, France in 2005 and a fellowship in Bone Marrow Transplant from and cancer Biology from Lyon-sud cancer center, Lyon, France in 2006. I have performed a training in Bone Marrow Transplant in San Rafaiele hospital in Milano and Ospedal Clinic in Barcelona. My main interest is cancer biology and translational research. I am also an editor and reviewer for more than 25 international reputable journals. My national and international publication exceeds 100 articles and I have published 4 books on lymphoma and pharmacology. I am an invited lecturer at the European institute of bone marrow transplant and OMICS group in Chicago.
- Michael J GonzalezUniversity of Puerto Rico
Dr. Michael J. Gonzalez is Professor at the Nutrition Program, School of Public Health in the Medical Sciences Campus, University of Puerto Rico and Adjunct faculty at the University of Western States. Dr. Gonzalez is a Fellow of the American College of Nutrition, and has authored over 200 scientific publications. He has serve as a member on several scientific Editorial Boards. He has served as consultant for several companies where he has been responsible for designing formulations of nutritional supplements and pharmaceutical products. He has also been a consultant for The Center for the Improvement of Human Functioning (now Riordan Clinic), in Wichita, Kansas. He has obtained several research awards for his work on Nutrition and Cancer. He is currently Director of RECNAC II project, and Research Director of the InBioMed Project Initiative. Dr. Gonzalez also serves as a nutrition consultant to the Puerto Rican Basketball National Team and is part of the Medical Commission of the Puerto Rican Basketball Federation. He was part of the Medical Staff of the Vaqueros de Bayamon professional basketball team. He is in a part time clinical practice with Dr. Miguel J Berdiel in Ponce, PR. In December 2013,Dr. Gonzalez was exalted as Distinguished Ponceño in Medicine. In 2015 he was selected as member to the prestigious Puerto Rican Academy of Arts and Sciences and to the Iberoamerican Academy of Culture and Sciences. Dr. Gonzalez was inducted to the International Hall of fame of Orthomolecular Medicine April, 2016. He is one of the first latino and Puerto Rican to be inducted to the International Hall of fame of Orthomolecular Medicine.
Doctor González is one of the founders of InBioMed, leaders in the development of non-toxic chemotherapy treatments for cancer. The findings of their work with Intravenous Vitamin C as an anti-cancer agent, published in 2002, were confirmed by the NIH in 2005. They published the first Phase-I clinical study utilizing Intravenous Vitamin C for treatment of terminal cancer patients in 2005, and also published in 2005 the most comprehensive review on Vitamin C and Cancer, as a follow-up on the work of two times Nobel Laureate, Dr. Linus C. Pauling and Dr. Hugh D. Riordan. Dr. Gonzalez has brought many new concepts into the scientific field, such as the Bioenergetic theory of carcinogenesis, the systemic saturation phenomenon of intravenous vitamin C, the metabolic correction concept for disease treatment and prevention, the physiological modulation and adaptogen explanation of the effect of phytomedicinals, the unified theory of the healthy state and mitochondrial correction as a therapeutic approach for chronic degenerative diseases. Books: Doctors Gonzalez, Miranda-Massari and Saul’s book “I Have Cancer What Should I do: The Orthomolecular Guide to Cancer Management” provides evidence based recommendations for an integrative approach for those dealing with cancer and seeking to improve quality of life and survival. In 2014 they published the book” New Insights Vitamin C and Cancer” for Springer-Larger. Dr. Gonzalez is actually finishing a book on Metabolic Correction and Diabetes and writing a chapter on metabolic correction and disease for a Functional medicine textbook.
- Francisco TorrensUniversitat De Valencia-ICMol
Francisco Torrens is lecturer in physical chemistry at the Universitat de València. After obtaining a PhD in molecular associations in azines and macrocycles from the Universitat de València, Dr. Torrens undertook postdoctoral research with Professor Rivail at the Université de Nancy I. More recently, Dr. Torrens has collaborated on projects with Professors Tomás-Vert, Salgado and Castellano. Major research projects include prediction of the environmental impact of chemical substances using chemobioinformatics tools, discovery of new inhibitors of tyrosinase: computational design, synthesis, characterization and experimental corroboration, search for new antimicrobial agents that inhibit the synthesis of the bacterial cell wall, minimal active domains of proteins of the Bcl 2 family, development and application of quantum chemistry methods and techniques to studies of drugs, analysis of pores of BAX at nanometric scale and study of the in vivo antioxidant capacity of phenolic compounds through QSAR/QSPR modelling: crossing of the blood-brain barrier and interactions with cytochromes and drugs. His scientific accomplishments include the first implementation in a computer at the Universitat de València of a program for the elucidation of crystallographic structures and the construction of the first computational-chemistry program adapted to a vector-facility supercomputer in a Spanish university.
Francisco Torrens research interest includes Theoretical chemistry; Physical chemistry; Mathematical chemistry; Computational chemistry; Molecular modelling; Simulation and design; Computer-aided drug design and development; Molecular graphics and representation of molecular properties.
- Rana Ahmed YounessGerman University
Rana Ahmed Youness is a currently a postdoc and assistant lecturer at the faculty of Pharmacy and Biotechnology, German University in Cairo (GUC), Egypt. Rana received her Bachelor degree with Excellence with Highest honors in 2013. She has awarded her MSc. degree in Pharmaceutical Biology Department at the age of 23 from the GUC. Her Master Thesis work has been acknowledged and published as a book under the title: “miR-486-5p and Liver cancer: A Beautiful Mind Act”. Moreover, her work has been ranked from top 10% posters in EASL conference (European Association for the Study of Liver Disease), Vienna, 2015. In 2018, she defended her PhD with a grade of “Summa Cum Laude” in the field of Gasotransmitters and its role in the molecular pathophysiology of Breast Cancer. Rana has published more than 8 publications in peer reviewed journals and more than 20 abstracts in prestigious conferences such as ESMO, EASL, AACR, EBCC, EACR, AASLD. She is currently an editor and reviewer in several peer reviewed journals related to the pharmaceutical Biology Department.
Rana’s research interest is unraveling the epigenetic mechanisms regulating the gasotransmitters’ machineries in the most aggressive and prevalent solid malignancies in Egypt such as Liver and Breast cancers. Moreover, she is currently focused on screening the Egyptian Flora for novel anticancer agents that potentially refine the de-regulated molecular pathways in the Egyptian cancer patients.
- Alireza HeidariCalifornia South University
Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Distinguished Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA. His research interests include Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, Synchrocyclotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc. He has participated at more than four hundreds reputed international conferences, seminars, congresses, symposiums and forums around the world as yet. Also, he possesses many published articles in Science Citation Index (SCI)/International Scientific Indexing (ISI), PubMed and Scopus Journals. It should be noted that he has visited many universities or scientific and academic research institutes in different countries such as United States, United Kingdom, Canada, Australia, New Zealand, Scotland, Ireland, Netherlands, Belgium, Denmark, Greece, Russia, Estonia, Ukraine, Turkey, France, Swiss, Germany, Sweden, Norway, Italy, Austria, Czech Republic, Hungary, Poland, South Africa, Egypt, Brazil, Spain, Portugal, Mexico, Japan, Singapore, Malaysia, Thailand, Taiwan, Hong Kong, South Korea, China, India, Qatar, United Arab Emirates, etc. as research fellow, sabbatical and volunteer researcher or visitor and so on heretofore. He has a history of several years of teaching for college students and various disciplines and trends in different universities. Moreover, he has been a senior advisor in various industry and factories. He is expert in many computer programs and programming languages. Hitherto, he has authored more than twenty books and book chapters in different fields of Chemistry. Syne, he has been awarded more than one thousand reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international and peer–reviewed journals, books and publishers. Hitherward, he is a member of more than four hundreds reputed international academic–scientific–research institutes around the world. It should be noted that he is currently the President of American International Standards Institute (AISI), Irvine, California, USA and also Director of the BioSpectroscopy Core Research Laboratory at California South University (CSU), Irvine, California, USA.
Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, Synchrocyclotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells
- Alain L FymatInternational Institute of Medicine & Science
DR. ALAIN L. FYMAT, BA, BS, MA, MS, PhD, PhD is a medical-physical scientist and an educator. He is the current President/CEO and Institute Professor at the International Institute of Medicine & Science with a previous appointment as Executive Vice President/Chief Operating Officer and Professor at the Weil Institute of Critical Care Medicine, California, U.S.A. He was formerly Professor of Radiology, Radiological Sciences, Radiation Oncology, Critical Care Medicine and Physics at several U.S. and European Universities. Earlier, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs (Office of Research Oversight). At the Loma Linda Veterans Affairs Medical Center, he was Scientific Director of Radiology, Director of the Magnetic Resonance Imaging Center and, for a time, Acting Chair of Radiology. Previously, he was also Director of the Division of Biomedical and Biobehavioral Research at the University of California at Los Angeles/Drew University of Medicine and Science and an Advisor to the U.S. National Academy of Sciences, National Research Council, for postdoctoral programs tenable at the California Institute of Technology. He is Health Advisor to the American Heart & Stroke Association, Coachella Valley Division, California. He has received numerous research grants from government, academia and private industry, and has consulted extensively with these entities. He has lectured extensively in several national and international academic, professional, governmental and industrial venues. He is a frequent Keynote Speaker and International Organizing Committee Member of several international scientific conferences. He has lectured extensively in the U.S., Europe, Asia and Africa. He has extensively published (~ 425 scholarly publications including patents, books & monographs, book chapters, refereed articles). He is also Editor-in-Chief, Honorable Editor or Editor of 62 medical/scientific Journals to which he contributes regularly. Dr. Fymat is a Board member of several institutions, a professional member of the New York Academy of Sciences and the European Union Academy of Sciences, and a reviewer for the prestigious UNESCO Newton Prize, United Kingdom National Commission for UNESCO.
DR. FYMAT's current research interests lie at the interface between medicine and science, particularly neurodegenerative disorders (Alzheimer, Parkinson, epilepsy, dementias and others), human genetics/ epigenetics/ ecogenetics, molecular/ personal/ precision medicine, and nanomedicine and nanobiotechnology.
- Nagendra LingarajScintilla Academy
Dr. Nagendra is the Director of BGS-BioMedical Research Institute, Bangalore and is the founder/ MD of Scintilla BIO-MARC Pvt. Ltd., and Scintilla Academy. In his previous positions, he was director of pediatric oncology and molecular pharmacology at Memorial Health University Medical Center, Savannah, GA, USA, and clinical development program at Dr. Reddy’s Laboratory, Hyderabad, India. He has undergraduate science degree, Masters in BIOCHEMISTRY from Mysore University and received PhD. in NEUROCHEMISTRY from the National Institute of Mental Health and Neurosciences. After moving to the USA in 1993, he earned a MBA from Mercer University, Atlanta, GA and performed his postdoctoral research in PHARMACOLOGY & TOXICOLOGY and MEDICINAL CHEMISTRY at the University of Kansas, KS. Dr. Nagendra then worked at Cedars Sinai Medical Center in LA, where he was a Group Leader and Principal Investigator in brain cancer and stroke research. He later moved to Vanderbilt University as Director of the neurooncology research laboratory. He has filed 12 patents from US, EU and Japan. He has over 100 peer-reviewed publications including several book chapters and presented in over 100 national and international scientific meetings. He had received research funding from the NIH, NCI, ACS, Georgia Cancer Coalition, and industry sponsors.
Translational clinical cancer research in the area of drug delivery and molecular cell biology of primary and metastatic breast cancers.
To study unique role of potassium channels in brain tumor growth and regulation of permeability in brain tumor vasculature.
To develop and patent novel anti-cancer drug delivery strategy to brain tumors
- Increasing evidence suggests that disruption of DNA methylation plays an important role in cancer development. Tumor cells exhibit global hypomethylation of the genome accompanied by region-specific hypermethylation. Global hypomethylation occurs mainly in the repetitive sequences leading to genomic instability while aberrant hypermethylation occurs at CpG-rich regions know as CpG islands in the promoter regions of genes. Hypermethylation of CpG islands, usually associated with transcriptional silencing, has been observed in all types of tumors including brain, with unique patters of individual gene methylation exhibited by each tumor type. In recent years there has been an increase in the use of genetic analysis in primary tumors towards the identification of molecular events and pathways involved in the etiology of brain tumors. However, our understanding of molecular basis of most of the cases remains poor.
- DNA methylation changes in brain cancer, particularly CpG island hypermethylation are very frequent and early events and the detection of these early events could lead to improved clinical outcomes. With the availability of robust and sensitive detection methods to detect DNA methylation (like methylation specific PCR (MSP)), identification of these aberrantly methylated CpG islands can serve as diagnostic biomarkers to detect presence of cancer cells or cancer-derived DNA in various bodily fluids like serum, plasma or urine. Further understanding of the function of these genes and their role in tumor development can form the basis for the design of novel therapeutic approaches.
- Research in our laboratory is focused on identifying and understanding the role of epigenetic events involved in brain tumor development and to use them as diagnostic or prognostic biomarkers. Using established cell lines and tissue samples from patients, representing various kinds / grades of brain tumors we would identify genes that are silenced as a result of promoter CpG island methylation. The aim is to establish an epigenetic signature for each tumor type with the goal of using these signatures to design targeted therapy.
- Enrico Maria AmadeiInfermi Hospital in Rimini
Dr. Enrico Maria Amadei currently working as an Otorhinolaryngologist at the Infermi Hospital in Rimini (Italy) since 2015. He graduated in Medicine and Surgery at the University "Alma Mater Studiorum" in Bologna in 2008 with honors. He acquired the specialization in Otorhinolaryngology at the university "Alma Mater Studiorum" in Bologna in 2014 with honors.
Dr. Enrico Maria Amadei participated in the review of numerous scientific articles (certificated on Publons). He also wrote some papers on the topic of ENT and published in international journals. He participated as a speaker at numerous national conferences.
- Bjbo.jinMedical Center of the General Hospital
Bo Jin is a Professor and Consulting Physician of the 8th Medical Center of the General Hospital of Chinese People’s Liberation Army in Beijing, China. He is also Editor-in-Chief of Journal of Clinical Gastroenterology and Treatment and Associate Editor-in-Chief of World Chinese Journal of Digestology. He was awarded his Bachelor of Medicine in 1985, Master in Infectious Diseases in 1990, and Doctor of Medicine in 2005. He completed his post-doctoral training for HCV research at NIH, USA in 2005 and was awarded the NIH Fellow’s Award for Research Excellence. He was also trained for liver fibrosis research at Toyama Medical and Pharmaceutical University, Japan for 1 year in 1996. He has published over 50 international and national articles as well as 5 medical book chapters.
viral hepatitis, liver fibrosis, cancer immunology, vaccine adjuvant, and gastrointestinal immunology.
- Eli E.BarCase Western Reserve University
Eli E.Bar is Assistant Professor, Department of Neurological Surgery Secondary Appointments in the Departments of Neuroscience & Molecular Biology and Microbiology School of Medicine, Case Western Reserve University and the Case Comprehensive Cancer Center Co-Director of the Case Comprehensive Cancer Center Athymic Animal and Preclinical Therapeutics Shared Resource (Athymic SR).
School: Tel-Aviv University
Degree: Bachelor of Science, Biology
School: University of Illinois at Chicago
Degree: Doctor of Philosophy, Molecular Biology
Institution: University of Illinois at Chicago
Institution: Johns Hopkins University, Department of Pathology, Division of Neuropathology
Position: Postdoctoral Fellow
University of Milan at Bicocca, Milan, Italy
Visiting Scholar, Studied cancer stem cells establishment and growth techniques; lab of Professor Angelo Vescovi
Case Western Reserve University School of Medicine, Neurological Surgery
2012 – present
Case Comprehensive Cancer Center
2016 – present
Case Comprehensive Cancer Center, Co-Director of the Case Comprehensive Cancer Center Athymic Animal and Preclinical Therapeutics Shared Resource (Athymic SR). 2018 - present
Adjunct Assistant Professor
Johns Hopkins University, Pathology, Division of Neuropathology
2012 – present
Lerner Research Institute, Cleveland Clinic, Department of Stem Cell Biology and Regenerative Medicine
2016 – present
Honors and Awards:
9th Annual Pathology Young Investigator Award for Excellence in Translational Research, 2007, 1st Prize
8th Annual Pathology Young Investigator Award for Excellence in Translational Research, 2006
- Giulio TarroFoundation T. & L de Beaumont Bonelli for cancer research Napoli
Dr Giulio Tarro was born on July 9,1938 in Messina, Sicily, Dr Tarro is currently engaged in scientific research related to the separation and identification of tumour antigens present on cell membranes and their potential value in immunotherapy for cancer. Dr Tarro began his medical studies at Messina University in 1956. In 1960 continued at Naples University from which he received his M.D."summa cum laude” in 1962. In 1965 he went to the Children's Hospital Research Foundation at the University of Cincinnati, where he worked with Dr Albert B. Sabin as a Research associate for three years and subsequently in 1968 and 1969 he was assistant Professor of Research Pediatrics at the same University Naples and established a virology laboratory at the Hospital for Infectious Diseases with the help of a Research Contract from the National Cancer lnstitute (U.S.A.)and the professorship for Oncological Virology in 1972. In 1973 Dr Tarro worked as Senior Scientist at the Frederick Cancer Research Center with Dr Albert Sabin, who was then a special consultant for the National Cancer lnstitute. His most notable work provided experimental evidence for the association of Herpes viruses with cancer of the cervix. Although at first controversial, this work has been carried out by several laboratories using different techniques. And has been elected for membership of many academies and societies. He has also been the recipient of many awards and honours. Dr Tarro is life president of the T. and L. de Beaumont Bonelli Foundation for Cancer Research officially recognized by Italian presidential decree n. 36 of January 3, 1978.During 1979 he was engaged in research on an epidemic disease in Naples called the "dark disease". isolated the respiratory syncytial virus (RSV) and found antibody evidence that this virus was behind the epidemic. Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus, 2006 -. Since 2007 Chairman Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010).
His basic researches have been concerned with antigens induced early during the replication cycle of human herpesviruses.
Another study has involved the identification, isolation and characterization of specific virus-induced tumour antigens, which were the “finger-prints” left behind in human cancer. Achievements include patents in field; discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas.
- Shyam ReddyMorehouse School of Medicine
Dr. Shyam Reddy is a Professor and Director, Cancer Biology Program, Department of OB/GYN, Morehouse School of Medicine, Georgia Cancer center for excellence, Grady Memorial Hospital, Atlanta, Ga. He carried out his Ph.D. work at the Center for Cellular and Molecular Biology, Hyderabad, India and at Max Planck Institute for Biophysical Chemistry, Gottingen, West Germany. His Ph.D. work was published as two papers (back to back) in the prestigious Nature journal for which he was awarded National Young Scientist award by the Prime minister of India. He obtained postdoctoral training in molecular biology at Yale University, CT (Dr Weissman, PNAS member). Dr Reddy discovered and cloned several cancer genes/oncogenes (close to 20 genes) and studied their functions. The most notable genes discovered by Dr Reddy include ERG-1, ERG-2, ERG-3 and human FLI-1genes. Drs Reddy and Rao named the gene as ERG (ETS Related Gene, published in prestigious journals Science and PNAS). ERG is a transcriptional factor, endothelial permeability factor and also a stem cell factor and is involved in 50-80% of Prostate cancers, Ewing sarcoma and also leukemias (AML). Other notable ETS genes discovered and studied by Dr Reddy include human Fli-1 (involved in 80% of Ewing family of tumors, Leukemias and Prostate cancer), EWS-Fli-1 (involved in 90% of Ewing Sarcoma, Pediatric cancer), EWS-erg (involved in Ewing Sarcoma), TLS-erg (involved in Acute Myeloid Leukemia), EWS (involved in multiple cancers), TLS/FUS (involved in multiple cancers), ELK-1 (Drs Reddy and Rao named this gene as ETS Like Gene, published in prestigious journals Science and Nature) and EWS-ATF-1 (malignant Melanoma of Soft Parts/Clear cell sarcoma). Dr Reddy and his group have also discovered novel post-translational mechanism mediated by BRCA2 in Breast Cancer cells that will have global effect on the Gene Expression, Protein turnover, Cell Death, Cancer and other Human diseases. Dr Reddy and his group have shown that ERG and FLI-1 proteins involved in several cancers are responsible for making cancer cells resistant to chemo-therapeutic agents. They are targeting these onco-proteins or their functions to develop novel targeted therapeutic agents. Using this strategy, they have developed several novel therapeutic agents (patent being submitted) that target Prostate cancer, Ewing Sarcoma, Breast cancer (including Triple Negative Breast Cancer), Pancreatic cancer, Ovarian cancer, cervical cancer, colorectal cancer, pancreatic cancer etc. These small molecules appear to be targeted therapeutic agents with no or little effect on normal cells. Dr Reddy received two grants from DOD to study on two targeted therapeutic agents against prostate cancer. Dr Reddy and his colleagues have also shown that anti-epileptic drug Valproic acid (VPA) targets ERG-positive Prostate cancers and Ewing Sarcoma and identified the molecular mechanism of action of VPA on ERG/Fli-1 associated cancers. Recently, they have identified novel ways by which ERG/ETS oncoproteins target different signaling pathways that leads to prostate and other cancers (leukemias, lymphomas and sarcomas). Dr Reddy and his colleagues have identified novel molecular mechanism of activation of TGF beta–signaling pathway by ERG oncoprotein in prostate cancer. Recently, Dr Reddy and his colleagues have shown that ETV1 onco-protein induces certain kinases in cancer cells which deregulate the critical Wnt/beta catenin pathway. They have also identified therapeutic agent that interferes with this process. They have also demonstrated that this therapeutic agent targets these cancer cells effectively (manuscript in press, 2016). These therapeutic agents will have a profound impact on prevention and treatment of prostate cancer which may help to reduce health disparity seen in minority prostate cancer patients. Recently, Dr Reddy’s group decoded non-coding DNA and it’s non-coding RNA and discovered novel tumor suppressors which will revolutionize tthe landscape of biology, diagnosis and therapy (In press, 2017, www.reddyesp.com ).
Molecular Oncology, Signaling pathways, Noncoding DNA and RNA, Therapeutic Strategies, Oncogenes, Fusion -oncogenes, Tumor Suppressors
- Veneela VasigalaNTR University of Health Sciences
Veneela Vasigala, MBBS is a medical doctor with 10 years of research and patient care experience. Dr.Vasigala has obtained her medical degree from NTR University of Health Sciences, India in 2009. Dr. Veneela's research interests include clinical development of novel cancer therapeutics. Dr. Veneela has published 12 original high impact articles, several invited reviews, abstracts, and book chapters. Dr. Veneela is an editorial board member for 2 international peer-reviewed journals and reviewer for 3 journals. Dr. Veneela has delivered several invited lectures and participated as conference organizing committee chair for several conferences.